{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T22:49:07Z","timestamp":1778798947471,"version":"3.51.4"},"reference-count":36,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"unspecified","delay-in-days":25,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100020276","name":"David Telling Charitable Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020276","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,3,7]]},"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Placental dysfunction is estimated to affect 10% of pregnancies and is associated with adverse perinatal outcomes. Low-dose aspirin (LDA) reduces placental dysfunction risk. However, adherence to LDA is suboptimal in pregnant women and may reduce its effectiveness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We aimed to explore the barriers and facilitators to LDA adherence in pregnant women with placental dysfunction risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Qualitative semi-structured individual interviews were undertaken, and data were inductively thematically analysed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>A single NHS Trust in South West England, UK.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Pregnant women aged&gt;18, recommended daily LDA for pregnancy indications. We purposively recruited those with a range of adherence patterns (non-adherent, suboptimally adherent, adherent).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      15\u2009women participated (93% white British, 73% university educated). Five were adherent (6\u20137 doses per week), five suboptimally adherent (4\u20135 doses per week) and five non-adherent (\n                      <jats:underline>&lt;<\/jats:underline>\n                      3 doses per week). Indications for LDA were pre-eclampsia risk, low PAPP-A and previous intrauterine growth restriction. Four themes and related subthemes were identified addressing motivational and implementation issues. Motivational barriers and facilitators included (1) risk perceptions: participants described limited understanding of their indications for LDA and the maternal and fetal impacts of placental dysfunction, feeling stigmatised by their body mass index being an indicator for LDA and perceiving it to be unlikely they would experience serious consequences of placental dysfunction. Facilitators were direct\/indirect experiences of placental dysfunction. (2) Concerns about taking LDA, including bleeding risk. (3) Interactions with healthcare professionals: participants described receiving limited information from healthcare professionals, with limited attention given to LDA compared with other antenatal recommendations. Distrust and trust in healthcare professionals impacted non-adherence\/adherence. Implementation barriers were (4) difficulties with establishing habits, tailing off and difficulties swallowing. Established habits and swallowing LDA whole supported taking it.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We identified motivational and implementation-related barriers and facilitators to LDA adherence in a clinical sample of women with placental dysfunction risk. Women require more information to enhance understanding and inform their decision, and require support to establish effective habits. Theory-informed behaviour change techniques could address these barriers. Adherence barriers and facilitators should be explored in minority ethnicity and economically deprived women, and healthcare staff providing LDA-related care to inform optimally effective interventions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-093888","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T10:36:51Z","timestamp":1742985411000},"page":"e093888","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Qualitative study exploring the barriers and facilitators to low-dose aspirin adherence in pregnant women with placental dysfunction risk in the UK"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0743-6547","authenticated-orcid":false,"given":"Anna","family":"Davies","sequence":"first","affiliation":[{"name":"Academic Women\u2019s Health Unit, Translational Health Sciences, University of Bristol, Bristol, UK"},{"name":"North Bristol NHS Trust, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7612-1605","authenticated-orcid":false,"given":"Sarah","family":"Chapman","sequence":"additional","affiliation":[{"name":"Department of Cancer and Pharmaceutical Science, King\u2019s College London Faculty of Life Sciences and Medicine, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadie","family":"Mullin","sequence":"additional","affiliation":[{"name":"Academic Women\u2019s Health Unit, Translational Health Sciences, University of Bristol, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1906-5069","authenticated-orcid":false,"given":"Danya","family":"Bakhbakhi","sequence":"additional","affiliation":[{"name":"Centre for Academic Women\u2019s Health, University of Bristol, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Neuberger","sequence":"additional","affiliation":[{"name":"North Bristol NHS Trust, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abigail","family":"Fraser","sequence":"additional","affiliation":[{"name":"NIHR Biomedical Research Centre, University of Bristol, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Williams","sequence":"additional","affiliation":[{"name":"Academic Women\u2019s Health Unit, Translational Health Sciences, University of Bristol, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christy","family":"Burden","sequence":"additional","affiliation":[{"name":"Centre for Academic Women\u2019s Health, University of Bristol, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"key":"2025121411554971000_15.3.e093888.1","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1016\/S0301-2115(03)00179-9","article-title":"Placental insufficiency and its consequences","volume":"110 Suppl 1","author":"Gagnon","year":"2003","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2025121411554971000_15.3.e093888.2","unstructured":"Wardinger JE , Ambati S . Placental insufficiency. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing LLC, 2024."},{"key":"2025121411554971000_15.3.e093888.3","doi-asserted-by":"publisher","DOI":"10.1002\/pd.1251"},{"key":"2025121411554971000_15.3.e093888.4","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10020179","article-title":"Women with a History of Recurrent Pregnancy Loss Are a High-Risk Population for Adverse Obstetrical Outcome: A Retrospective Cohort Study","volume":"10","author":"Rasmark Roepke","year":"2021","journal-title":"J Clin Med"},{"key":"2025121411554971000_15.3.e093888.5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.8551"},{"key":"2025121411554971000_15.3.e093888.6","article-title":"Antiplatelet agents for preventing pre-eclampsia and its complications","volume":"2019","author":"Duley","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121411554971000_15.3.e093888.7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0247782","article-title":"Dose of aspirin to prevent preterm preeclampsia in women with moderate or high-risk factors: A systematic review and meta-analysis","volume":"16","author":"Van Doorn","year":"2021","journal-title":"PLoS One"},{"key":"2025121411554971000_15.3.e093888.8","unstructured":"National Institute for Health and Care Excellence . Hypertension in pregnancy quality standard (QS35). NICE, 2019. Available: https:\/\/www.nice.org.uk\/guidance\/qs35"},{"key":"2025121411554971000_15.3.e093888.9","unstructured":"NHS England . Saving babies\u2019 lives care bundle version 2. 2019."},{"key":"2025121411554971000_15.3.e093888.10","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ajog.2017.08.110","article-title":"Aspirin for Evidence-Based Preeclampsia Prevention trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia","volume":"217","author":"Wright","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"2025121411554971000_15.3.e093888.11","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-004365","article-title":"Medication use in pregnancy: a cross-sectional, multinational web-based study","volume":"4","author":"Lupattelli","year":"2014","journal-title":"BMJ Open"},{"key":"2025121411554971000_15.3.e093888.12","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1111\/bcp.15609","article-title":"Adherence to prescription medication during pregnancy: Do pregnant women use pharmacological treatment as prescribed?","volume":"89","author":"de Korte","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"2025121411554971000_15.3.e093888.13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0229622","article-title":"Factors that influence adherence to aspirin therapy in the prevention of preeclampsia amongst high-risk pregnant women: A mixed method analysis","volume":"15","author":"Shanmugalingam","year":"2020","journal-title":"PLoS One"},{"key":"2025121411554971000_15.3.e093888.14","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.preghy.2016.08.232","article-title":"Aspirin adherence during high-risk pregnancies, a questionnaire study","volume":"6","author":"Abheiden","year":"2016","journal-title":"Pregnancy Hypertens"},{"key":"2025121411554971000_15.3.e093888.15","doi-asserted-by":"crossref","DOI":"10.1186\/s12884-022-05218-5","article-title":"Interventions to enhance medication adherence in pregnancy- a systematic review","volume":"23","author":"Davies","year":"2023","journal-title":"BMC Pregnancy Childbirth"},{"key":"2025121411554971000_15.3.e093888.16","article-title":"Interventions for enhancing medication adherence","volume":"2014","author":"Nieuwlaat","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121411554971000_15.3.e093888.17","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2018-001725"},{"key":"2025121411554971000_15.3.e093888.18","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-009-0744-2"},{"key":"2025121411554971000_15.3.e093888.19","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s10995-017-2358-0","article-title":"Making Decisions About Medication Use During Pregnancy: Implications for Communication Strategies","volume":"22","author":"Lynch","year":"2018","journal-title":"Matern Child Health J"},{"key":"2025121411554971000_15.3.e093888.20","doi-asserted-by":"crossref","first-page":"100663","DOI":"10.1016\/j.ajogmf.2022.100663","article-title":"Assessment of adherence to aspirin for preeclampsia prophylaxis and reasons for nonadherence","volume":"4","author":"Olson","year":"2022","journal-title":"Am J Obstet Gynecol MFM"},{"key":"2025121411554971000_15.3.e093888.21","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.preghy.2021.06.006","article-title":"Informational needs related to aspirin prophylactic therapy amongst pregnant women at risk of preeclampsia - A qualitative study","volume":"25","author":"Vinogradov","year":"2021","journal-title":"Pregnancy Hypertens"},{"key":"2025121411554971000_15.3.e093888.22","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1080\/21642850.2021.1951273","article-title":"Aspirin non-adherence in pregnant women at risk of preeclampsia (ANA): a qualitative study","volume":"9","author":"Vinogradov","year":"2021","journal-title":"Health Psychol Behav Med"},{"key":"2025121411554971000_15.3.e093888.23","doi-asserted-by":"publisher","DOI":"10.1093\/intqhc\/mzm042"},{"key":"2025121411554971000_15.3.e093888.24","unstructured":"National Institute for Health and Care Excellence . Hypertension in pregnancy: diagnosis and management. 2019. Available: https:\/\/www.nice.org.uk\/guidance\/ng133\/chapter\/recommendations"},{"key":"2025121411554971000_15.3.e093888.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"2025121411554971000_15.3.e093888.26","doi-asserted-by":"publisher","DOI":"10.1177\/1049732315617444"},{"key":"2025121411554971000_15.3.e093888.27","doi-asserted-by":"crossref","unstructured":"Vinogradov R , Kavanagh ON , Palmer J , et al . A randomized crossover design study comparing the pharmacokinetics and pharmacodynamics of 2 single doses of oral aspirin (75 mg v 150 mg) in pregnant women at risk of preeclampsia: implications on assessing aspirin response and patient adherence to therapy. Am J Obstet Gynecol 2024.:S0002-9378(24)01084-6. doi:10.1016\/j.ajog.2024.10.023","DOI":"10.1016\/j.ajog.2024.10.023"},{"key":"2025121411554971000_15.3.e093888.28","doi-asserted-by":"publisher","DOI":"10.1136\/qshc.2004.011155"},{"key":"2025121411554971000_15.3.e093888.29","doi-asserted-by":"publisher","DOI":"10.1191\/1478088706qp063oa"},{"key":"2025121411554971000_15.3.e093888.30","first-page":"283","article-title":"Racial\/ethnic differences in pregnancy-related hypertensive disease in nulliparous women","volume":"24","author":"Ghosh","year":"2014","journal-title":"Ethn Dis"},{"key":"2025121411554971000_15.3.e093888.31","unstructured":"MBBRACE-UK . Saving lives, improving mothers\u2019 care: core report: lessons learned to inform maternity care from the UK and Ireland confidential enquiries into maternal deaths and morbidity 2018-20. 2022."},{"key":"2025121411554971000_15.3.e093888.32","doi-asserted-by":"publisher","DOI":"10.1186\/1748-5908-6-42"},{"key":"2025121411554971000_15.3.e093888.33","doi-asserted-by":"publisher","DOI":"10.1007\/s12160-013-9486-6"},{"key":"2025121411554971000_15.3.e093888.34","first-page":"693","article-title":"Behavior Change Techniques and Their Mechanisms of Action: A Synthesis of Links Described in Published Intervention Literature","volume":"53","author":"Carey","year":"2019","journal-title":"Ann Behav Med"},{"key":"2025121411554971000_15.3.e093888.35","doi-asserted-by":"crossref","DOI":"10.1186\/s13012-019-0913-3","article-title":"Investigating midwives\u2019 barriers and facilitators to multiple health promotion practice behaviours: a qualitative study using the theoretical domains framework","volume":"14","author":"McLellan","year":"2019","journal-title":"Implement Sci"},{"key":"2025121411554971000_15.3.e093888.36","doi-asserted-by":"crossref","DOI":"10.1186\/s12978-019-0707-8","article-title":"Views and preferences of medical professionals and pregnant women about a novel primary prevention intervention for hypertensive disorders of pregnancy: a qualitative study","volume":"16","author":"Vestering","year":"2019","journal-title":"Reprod Health"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-093888","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T19:56:02Z","timestamp":1765742162000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-093888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,26]]},"published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1136\/bmjopen-2024-093888"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-093888","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]}}}